🔗 Share this article

Given that America continues making sweeping revisions to its vaccine recommendations, one figure appears unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about Covid vaccinations in the global health crisis and has concentrated on potential deaths after Covid immunization in her short position at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Agency leaders had intended to announce major revisions to the pediatric vaccination calendar earlier this month, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would place the US out of step with a large portion of the global community with no evidence for benefit. The announcement has been delayed until the next year.

In place of the top vaccines chief, Høeg is scheduled to address the audience at the meeting. She was just designated acting director of the FDA’s CDER, the fifth individual to head the division this calendar year.

Consolidating Power at the Agency

The acting appointment could signify a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a renewed priority upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric immunization guidelines in the US to become more in line with the Danish model, a society with universal health coverage and a population roughly the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of medication approval.

Questions Over Qualifications

Høeg has little discernible background in drug development, oversight or management, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in running a large organization. She is not an expert in drug approvals.”

Past heads of the center would “be deeply familiar with legal statutes and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that prior appointees who led CBER have had.”

CDER has an vast workload at the agency, the former commissioner pointed out.

“The public just pays attention on the novel medication approvals, but the off-patent medication office approves a multitude of generic medications. There’s a biosimilars program, OTC medication office and other areas, and each of these must be looked after,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative component to the job, which oversees more than 5,000 employees. “It’s a enormous administrative position, if you execute it properly,” she concluded.

Official Statement and Contentious Initiatives

When asked about inquiries about Høeg’s qualifications and whether this assignment indicates increased cooperation among FDA leaders on vaccines, a representative responded that the “concerns stem from inaccurate premises”.

“Her resume is consistent with the duties of her role,” the official said, pointing to the time Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s new expedited review system, a contentious expedited medication authorization process that allegedly concerned her predecessors. “By what process are these therapies being chosen for this voucher program? Who is making the calls?” Howard asked. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards more relaxed rules of all drugs, with the exception of immunizations.”

Established Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if troubling, track record, Howard have noted. She authored a analysis using unconfirmed public submissions to assess the incidence of heart inflammation after Covid immunization. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the new federal leadership featured altering rules for novel immunizations and halting “non-essential” vaccines, she said post-election on a online show. At the agency, Høeg has reportedly suggested excluding teenage boys from obtaining COVID-19 vaccines.

“She is an all-around true believer who starts off with her preconceived notions and reverse-engineers to retrofit the science in a extremely disingenuous, fraudulent way,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow dissenters, {like|